Dabur Pharma eyes foray into cancer diagnostic services
Pummy Kaul – New Delhi
THE Rs 183.8-crore Dabur Pharmaceuticals Ltd is exploring business opportunities in the sophisticated diagnostic services and may set up branded diagnostic centres in the country.
The company, sources say, is seriously looking at offering high quality diagnostic services for chronic diseases like cancer or oncology, a focus area for Dabur Pharma. The company is likely to offer these services to either corporate hospitals or may set up its own chain of diagnosis outlets which will be branded ‘Dabur Onquest’ across the country.
Dabur Pharma refused to give details about the proposed project. Dabur Pharma CEO Ajay Kumar Vij, when contacted, said it was too early to talk about the project. It is however not known whether the company will join hands with any global pharma major for the proposed project or will go alone.
Already a leader in the oncology segment in India, Dabur Pharma’s long-term growth strategy is to be a major player in the global oncology generics business, supplementing its own strengths in this area by entering into key alliances with pharma majors. The diagnostic services segment has recently begun to get organised in the country with major players like Ranbaxy and Apollo in the fray.
Dr Lal’s – a player which has restricted itself to the North – is another strong contender. However, most of these are present in the general health diagnosis segment. Dabur, on the other hand, is looking at offering specialised diagnostics for cancer only.
— Financial Express